


# ACT-A Prioritized Strategy & Budget for 2021

---


4<sup>th</sup> Facilitation Council

9 FEBRUARY 2021

ACT now, ACT together to accelerate the end of the COVID-19 crisis



# COVID-19 has claimed >2 million lives, with >100 million confirmed cases



# ACT-Accelerator made a real difference in 2020, laying the groundwork for **3 robust lines of defense** against COVID-19 globally in 2021



## Vaccines: COVID-19 infection can be prevented everywhere

COVAX Facility & products have transformed the outlook for vaccination, with the capacity to distribute **>2Bn vaccine doses in 190 countries & economies**



## Tests: COVID-19 disease can now be detected anywhere

New, affordable & high-quality Rapid Diagnostics (RDTs) transform our capacity to detect infection anywhere, with access to **>375 m low-cost tests for LMICs**



## Treatment: life-threatening illness can be treated anywhere

**Dexamethasone**, the first and only proven therapy for severe COVID-19 has transformed our ability to save lives, with global guidance and an urgent stockpile of **2.9 m courses**



**Equitable Access:** crucial investments to ensure access & stimulate update, everywhere




**Global Access & Allocation Framework & COVAX Mechanisms**



**Catalytic health systems support** to deliver new products & PPE

# Many generous supporters have contributed to ACT Accelerator success



**ACT-A contributions** – in % of total commitments<sup>1</sup>, as of 3 February 2021

**US\$ 4 billion additional for vaccine procurement & delivery is being finalized with the United States**

Note: all financial commitments can be accessed at <https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker>.

1. US\$ 6 billion include \$470m contributed by the Diagnostics Consortium to procure automated and manual molecular tests for LMICs

2. Excluding US\$ 267m by donors to the Global Fund COVID-19 Response Mechanism and redistributed to ACT-A pillars 3. Contributions <US\$ 20m

## 3 big shifts inform the 2021 ACT-A Strategy & Budget



We have entered the **era of COVID-19 vaccines**




**Viral variants** are emerging with increasingly concerning characteristics




**International collaboration** is increasingly fragmented & underinvesting in global solutions

COVID-19 vaccine doses administered/100 people



Variants of concern in > 100 countries



**A strong global, integrated and agile response is crucial:  
scaling up tools while adapting to an evolving context**



# ACT-Accelerator is releasing a new, prioritized & integrated strategy for 2021

**ACT Accelerator**  
ACCESS TO COVID-19 TOOLS

## ACT-Accelerator Prioritized Strategy & Budget for 2021

Consultation Draft of 03 February 2021

Working with governments, civil society and industry

### 01

#### ACT-ACCELERATOR IS EVOLVING IN A RAPIDLY CHANGING WORLD

- The evolving context is characterized by 3 main shifts:
1. We have entered the 'era of COVID-19 Vaccines'
  2. Viral variants are emerging with increasingly concerning characteristics
  3. The international collaboration in responding to the COVID-19 pandemic is increasingly fragmented and underinvesting in global solutions

The world continues to deal with an unprecedented threat, which extends far beyond a global health crisis. We are facing an economic, humanitarian, security and human rights crisis. One human, social and economic challenge has been unfolding, and countries have spent trillions on the consequences of COVID-19. As of late January 2021, COVID-19 has claimed more than 2 million lives and infected 100 million people worldwide. Many countries are experiencing a resurgence in cases, often more extreme than previous waves. New and more transmissible variants of the virus are taking hold in many geographies. We need to do much more and act much faster to save lives, stabilize health systems and restore global economic momentum.

The Access to COVID-19 Tools (ACT) Accelerator, launched in April 2020, is a global solution for expediting the end of the COVID-19 pandemic. This collaboration of leading public health agencies has accelerated the development of COVID-19 vaccines, diagnostics and therapeutics and is positioned to rapidly scale and ensure equitable access to a new generation of COVID-19 tools on a global scale.

### 03

#### IN 2021, ACT-ACCELERATOR IS DRIVING FOR EQUITY IN THE DELIVERY OF ESSENTIAL TOOLS WHILE MANAGING EMERGING VIRAL RISKS

- The arrival of vaccines vaccine supply, an ever rapidly changing public history requires a high investment case. We response, and deliver to ensure research and of the pandemic control strategy, priorities, etc.
1. We have entered the 'era of COVID-19 Vaccines'

ACT Accelerator: Status Organizational, 2020 (13 January 2021)  
ACT Accelerator: Urgent Health Organization, 2020 (13 January 2021)  
ACT Accelerator: An ever rapidly changing public history requires a high investment case. We response, and deliver to ensure research and of the pandemic control strategy, priorities, etc.

#### ACT A's Strategic Priorities for 2021

1. Rapidly scale-up the delivery of over 2 billion doses of vaccines through COVAX to the most high risk and highly exposed populations globally
2. Respond to emerging variants and programmatic needs
3. Enhance and catalyze the utilization of COVID-19 diagnostics, therapeutics and PPE
4. Ensure a robust supply of essential COVID-19 tools, to be achieved by focusing on four main priorities for 2021

#### Key strategic priorities for ACT-Accelerator in 2021


In 2021, ACT Accelerator and the global COVID-19 response have the opportunity to move from being reactive to proactive to gain back control and ultimately overcome the pandemic. The recent critical shifts described above require adjustment of the ACT Accelerator priorities to achieve its goal of accelerating the development and equitable access of COVID-19 tools. Given the continuous evolution of the virus, epidemiology and global landscape, ACT Accelerator will remain flexible and agile in addressing and adjusting its priorities over the course of the year. ACT Accelerator will drive for equity in the delivery and continuous improvement of essential COVID-19 tools, to be achieved by focusing on four main priorities for 2021:

1. Rapidly scale-up the delivery of over 2 billion doses of vaccines through COVAX to the most high risk and highly exposed populations globally

To end the pandemic, people everywhere, particularly the most vulnerable populations, need rapid access to the vaccine. This is critical for equity, advancing global health security, and getting our economies back on track. COVAX is making significant strides towards addressing some of the vaccine inequities, with the Top LIC and LMICs similar to the 10 weeks of the introduction in most HICs, and we require the challenges presented. Further work will be required to ensure that all populations have rapid access to the vaccine.



Figure 3 - ACT-Accelerator within a broader need for COVID-19 tools - in US\$ billion



In 2021 ACT-A has four strategic priorities, driving for equity in the delivery of COVID-19 tools, while continuously improving these tools



1

Rapidly scale-up **delivery of >2 B vaccine doses** with COVAX Facility

2

Bolster R&D, evaluation & regulatory pathways to **optimize products & address variants**

3

Stimulate rapid & effective **uptake of tests, therapeutics & PPE** in LICs/LMICs

4

Ensure **robust supply pipeline** of essential tests, therapeutics & PPE for LICs/LMICs


Pillar-specific priorities & deliverables underpin the ACT-Accelerator's **4 cross-cutting, strategic priorities**

# US\$27.2 Bn is needed for ACT-Accelerator Strategic Priorities in 2021

**1** Rapidly scale-up **delivery of >2 B doses of vaccine** through the COVAX Facility

**2** Bolster R&D, evaluation & regulatory pathways, to **optimize products & also address variants**


**3** Stimulate rapid & effective **uptake of tests, treatments & PPE** in LIC/LMICs



**4** Ensure **robust supply pipeline** of essential tests, treatments & PPE for LICs/LMICs



The ACT-Accelerator has built a detailed view of its agency-specific deliverables & funding needs for 2021




COVID-19 is an unstable international crisis

A global solution is essential to recovery

ACT Accelerator now has the tools & access platforms


Scaled multilateral response now required



---

Working slides (backup)

# ACT-Accelerator needs are catalytic within broader COVID-19 requirements



# Pillar-specific priorities for 2021



## Vaccines

1. **Ensure equitable access and fair allocation**
2. **Ensure delivery at scale** of 2bn doses & provide country support
3. **Accelerate further development of safe, efficacious and programmatically-optimized vaccines** to address new risks



## Diagnostics

1. **Secure equitable access to tests:** procurement of 900 mn tests
2. **Stimulate rapid & effective uptake in countries**
3. **Drive development and at-scale availability of affordable, transformative, digitally-integrated tests**



## Therapeutics

1. **Intensify research efforts:** develop clinical pipeline & broaden portfolio, incl. combinations
2. **Ensure market readiness and access & support countries** in optimizing clinical care
3. **Drive successful uptake and scaled procurement** of available therapeutics, incl. O<sub>2</sub>



## Health Systems Connector

1. **Contribute to the identification of key health systems bottlenecks in countries**
2. **Support countries to address the health system bottlenecks** or weaknesses identified
3. **Accelerate the availability of PPE** as high priority commodity

# Pledges & Cost Adjustments have brought the ACT-Accelerator US\$ 38.1 billion budget to a gap of US\$ 27.2 billion for 2021


Last update: 03 Feb 2021

**ACT-A funding gap, in USD billion**

Not yet allocated to pillars
  Vaccines
  Therapeutics
  Diagnostics
  Health Systems

US\$ 27.2 billion not including:

- US\$ 322 million not yet allocated to pillars
- US government US\$ 4 billion funding for Vaccine delivery and procurement still under negotiation



1. Includes US\$ 322 million not yet allocated to Pillars and US\$ 100 million applied against 2020 costs

2. US\$ 0.8 billion of procurement need for Oxygen moved from the Health Systems Connector to the Therapeutics Pillar



# ACT-A funding gap by Pillar & Strategic Priority, 2021

Last update: 03 Feb 2021

## by Pillar

USD billion

	Q1/Q2 2021	Q3/Q4 2021	Total 2021
Diagnostics	1.9	7.0	8.9
Therapeutics	1.4	1.8	3.2
Vaccines	7.8	<0.1	7.8
Health Systems Connector	3.2	4.3	7.4
<b>Total</b>	<b>14.2</b>	<b>13.1</b>	<b>27.2</b>

## by Strategic Priority

### Priority

USD billion

	Q1/Q2 2021	Q3/Q4 2021	Total 2021
1. Rapidly scale delivery of 2 billion vaccines doses through COVAX	6.4	<0.1	6.4
2. Bolster R&D, product evaluation & regulatory pathways	1.6	0.2	1.8
3. Enhance use of diagnostics (Dx), therapeutics (Tx) & PPE in LMICs	2.0	3.8	5.8
4. Ensure robust supply pipeline of essential Dx, Tx & PPE for LMICs	4.2	9.0	13.2
<b>Total</b>	<b>14.2</b>	<b>13.1</b>	<b>27.2</b>

Note: numbers are rounded to closest figure